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Methods:	 PwHA	with	 inhibitors	 aged	 ≥12	years	 previously	 on	 episodic	 bypassing	
agents	 (BPAs)	were	 randomized	 to	 emicizumab	 prophylaxis	 (Arm	A;	 n	=	35)	 or	 no	
prophylaxis	 (Arm	 B;	 n	=	18);	 participants	 previously	 on	 BPA	 prophylaxis	 received	
emicizumab	prophylaxis	(Arm	C;	n	=	49).	Health‐related	outcomes	assessed	at	base‐
line	and	monthly	 thereafter:	Haemophilia	Quality	of	Life	Questionnaire	 for	Adults	
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1  | INTRODUC TION
Despite	advances	in	the	treatment	of	haemophilia	A	in	the	past	de‐




the	first	10‐15	days	of	 treatment.4,5	 Inhibitors	are	classified	as	 low	
titre	 (<5	 Bethesda	 units	 [BU]/mL)	 or	 high	 titre	 (>5	BU/mL	 at	 least	
once)	based	on	the	highest	documented	 inhibitor	 level	and	the	oc‐
currence	of	an	anamnestic	response	after	re‐exposure	to	factor	con‐















PwHA	with	 inhibitors	 have	 significant	 breakthrough	 bleeding,10,12 
and	 often	 experience	 poor	 health‐related	 quality	 of	 life	 (HRQoL),	
increased	health	care	costs,	joint	pain	and	other	orthopaedic	issues,	
and	missed	days	of	work	and	school	due	to	bleeding.22‐26
Emicizumab	 (HEMLIBRA®;	 F.	 Hoffmann‐La	 Roche,	 Basel,	
Switzerland)	 was	 developed	 to	 address	 the	 unmet	 needs	 of	
PwHA	with	 inhibitors	 for	 effective,	 less	 burdensome	 prophylaxis.	
Emicizumab	 is	 a	 humanized	 bispecific	 antibody	 that	 bridges	 acti‐
vated	factor	IX	and	factor	X,	restoring	the	function	of	missing	acti‐
vated	FVIII	and	haemostasis	even	in	the	presence	of	FVIII	inhibitors.	
High	 subcutaneous	 bioavailability27	 and	 a	 4‐	 to	 5‐week	 half‐life28 
allow	emicizumab	to	be	administered	subcutaneously	once	weekly.29 
Emicizumab	has	been	approved	in	several	countries	for	prophylaxis	





versus	 no	 prophylaxis.	 Annualized	 bleeding	 rate	 (95%	 confidence	




were	 experienced	 by	 63%	 on	 emicizumab	 prophylaxis	 and	 6%	 on	
no	prophylaxis.	In	an	intra‐individual	comparison	among	those	pre‐
viously	 using	BPA	prophylaxis	 in	 a	 prospective	 non‐interventional	
study	 (NIS;	 NCT02476942),	 emicizumab	 prophylaxis	 resulted	 in	 a	
79%	decrease	in	bleeding	rates	(P	<	0.001).29
The	purpose	of	 the	present	 paper	 is	 to	 provide	 a	 detailed	 de‐
scription	of	HRQoL	and	health	status	outcomes	in	PwHA	with	inhib‐
itors	in	HAVEN	1.
2  | MATERIAL S AND METHODS
HAVEN	1	was	a	multicentre,	open‐label,	 randomized,	Phase	3	trial	











interval)	 favoured	Arm	A	versus	B	 for	Haem‐A‐QoL	“Total”	 score	 (14.0	 [5.6,	22.5];	
P	=	0.002)	 and	 “Physical	Health”	 (21.6	 [7.9,	 35.2];	P	=	0.003);	 EQ‐VAS	 (−9.7	 [−17.6,	
−1.82];	P	=	0.017);	and	IUS	(−0.16	[−0.25,	−0.07];	P	=	0.001);	mean	scores	are	compa‐
rable	in	Arms	A	and	C.	Throughout	the	study,	a	greater	proportion	of	participants	on	





K E Y W O R D S
emicizumab,	factor	VIII	inhibitors,	haemophilia	A,	health‐related	quality	of	life,	prophylaxis
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Participants	 on	 episodic	 BPA	 treatment	 before	 study	 entry	




participated	 in	 the	NIS,	but	were	unable	to	enrol	 into	Arms	A,	B	








Haemophilia Quality of Life Questionnaire for Adults 
(Haem‐A‐QoL)
The	Haem‐A‐QoL	 is	 a	 validated,	 haemophilia‐specific	 instrument	 for	
evaluating	HRQoL	in	PwHA	aged	≥18	years.30‐32	This	46‐item	measure	
consists	of	10	domains	(“Physical	Health,”	“Feelings,”	“View	of	Yourself,”	
“Sports	 &	 Leisure,”	 “Work	 &	 School,”	 “Dealing	 with	 Haemophilia,”	








Haemophilia‐specific Quality of Life assessment for children 
and adolescents Short Form (Haemo‐QoL SF)
The	Haemo‐QoL	SF	is	a	validated,	haemophilia‐specific	instrument	
for	evaluating	HRQoL	 in	PwHA	 in	 two	age	groups	 (I:	4‐7	years;	 II:	
8‐17	years).33	 The	 35‐item	measure	 for	 age	 group	 II	 is	 composed	
of	 nine	 domains	 (“Physical	 Health,”	 “Feelings,”	 “View	 of	 Yourself,”	
“Family,”	 “Friends,”	 “Other	 People,”	 “Sports	 &	 School,”	 “Dealing	
with	 Haemophilia”	 and	 “Treatment”),	 each	 scored	 separately	 and	
combined	to	create	a	“Total”	score.	Response	options	ranged	from	
“Never”	(1)	to	“Always”	(5)	on	a	5‐point	Likert	scale.	Some	items	of	
the	 domains	 “View	 of	 Yourself”,	 “Friends,”	 “Sports	 &	 School”	 and	
“Dealing	with	Haemophilia”	were	reverse‐scored	as	above.









sion;	 each	with	 five	 levels	 of	 severity	 ranging	 from	 “no	problems”	
to	“extreme	problems”.35,36	The	five	dimensions	were	combined	into	
an	index	utility	score	(IUS)	using	the	UK	crosswalk	value	set;	scores	
range	 from	−0.594	 (extreme	problems	 on	 all	 dimensions)	 to	 1	 (no	
problems	 on	 all	 dimensions).37	 On	 the	 EQ‐VAS,	 participants	 indi‐
cated	 their	health	 status	on	a	 thermometer	 ranging	 from	0	 (worst	
imaginable)	 to	100	 (best	 imaginable).	 For	both	EQ‐5D‐5L	 and	EQ‐
VAS,	participants	were	asked	to	report	the	severity	experienced	on	
the	day	the	questionnaire	was	completed.
2.1.3 | Work and school absences





















PwHA with inhibitors on
episodic/prophylactic treatment
with BPAs (from non-
interventional study)b 
(n = 7)   
Emicizumab
Primary analysis:
      ≥24 wk follow-up in Arms A and B
Prior episodic treatment
(n = 53) 
Prior prophylactic treatment
(n = 49) 
No prophylaxis (n = 18)
Emicizumab (n = 35)
Emicizumab
Emicizumab (n = 49) Emicizumab
Arm A
Emicizumab
Arm B (control arm) 
Arm C
Arm D
PwHA with inhibitors aged ≥12 y
on treatment with BPAsa (N = 109)
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2.2 | Data collection and analysis
All	 outcomes,	 except	 for	 hospitalizations,	 were	 recorded	 by	 par‐
ticipants	 using	 an	 electronic,	 handheld	 device	 provided	 during	
the	week	 1	 visit	 and	 before	 administration	 of	 study	medication.	
Participants	were	asked	to	record	all	HRQoL	and	health	status	out‐
comes	every	4	weeks.	In	addition	to	scheduled	assessments,	they	
were	 asked	 to	 complete	 the	 EQ‐5D‐5L	 on	 any	 day	 during	which	
bleeding	occurred.
Demographic	data,	medical	history	and	hospitalizations	were	
collected	 from	 participants’	medical	 records	 on	 an	 eCRF	 by	 cli‐
nicians.	Analysis	of	covariance	(model	 included	treatment	group,	
baseline	 score	 and	 the	 treatment‐by‐baseline	 interaction	 term	
as	 covariates)	 was	 used	 to	 compare	 the	 adjusted	 mean	 scores	
for	 Haem‐A‐QoL	 “Physical	 Health”	 and	 “Total”	 score	 and	 the	
EQ‐5D‐5L	 IUS	 and	EQ‐VAS	between	Arms	A	 and	B	which	were	
included	 as	 type	 1	 error‐controlled	 secondary	 endpoints.	 The	
analysis	 of	 EQ‐5D‐5L	 IUS	 and	 EQ‐VAS	 when	 a	 bleed	 occurred	
(unscheduled	 assessments)	 as	 compared	 with	 when	 no	 bleed	
occurred	 (monthly	 scheduled	 assessments)	 only	 included	 par‐









The	 rate	 of	 participant	 compliance	 with	 the	 completion	 of	







The	 participant	 population	 for	 the	 HAVEN	 1	 study	 has	 been	 de‐
scribed	 previously29	 and	 is	 summarized	 briefly	 here.	 Participants	








TA B L E  1  Participant	demographics	and	baseline	characteristics29
Characteristic
Previously on episodic BPAsa
Previously on 
prophylactic BPAsa
Arm A: Emicizumab 
prophylaxis (n = 35) Arm B: No prophylaxis (n = 18)
Arm C: Emicizumab 
prophylaxis (n = 49)
Median	age,	y	(range) 38.0	(12‐68) 35.5	(13‐65) 17.0	(12‐75)
Age	groups
<18	y,	n	(%) 4	(11.4) 2	(11.1) 26	(53.1)
≥18	y,	n	(%) 31	(88.6) 16	(88.9) 23	(46.9)
Race,	n	(%)
Asian 10	(28.6) 3	(16.7) 8	(1.36)
Black	or	African	American 4	(11.4) 4	(22.2) 3	(6.1)
White 21	(60.0) 10	(55.6) 33	(67.3)
Otherb 0	(0.0) 1	(5.6) 5	(10.2)
Bleeding	events	in	previous	24	wk,	n	(%)
<9 11	(31.4) 5	(27.8) 23	(46.9)
≥9 24	(68.6) 13	(72.2) 26	(53.1)
Severe	haemophilia	at	baseline,	n	(%) 31	(88.6) 18	(100.0) 47	(95.9)
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3.1.1 | Compliance
Compliance	 with	 completion	 of	 all	 questionnaires	 across	 all	 time	
points	was	≥90%	for	all	outcome	measures	in	all	treatment	arms.




Improvements	 in	 Haem‐A‐QoL	 domain	 and	 total	 scores	 with	
emicizumab	prophylaxis	were	seen	as	early	as	week	5,	maintained	
through	week	25	and	generally	similar	regardless	of	previous	treat‐




















group	 (Arm	B)	 in	 “Total”	 or	 domain	 scores	 at	 any	 time	 during	 the	
study.
3.1.3 | Haemophilia‐specific Quality of Life in 
adolescents (Haemo‐QoL SF)
The	 impact	of	emicizumab	prophylaxis	on	Haemo‐QoL	SF	 is	only	
presented	 for	 those	 participants	 previously	 treated	 with	 pro‐
phylactic	 BPAs	 (Arm	C)	 because	 too	 few	 adolescents	 completed	








At	baseline,	mean	 (95%	CI)	 EQ‐VAS	 scores	were	70.7	 (63.6,	 77.9),	
76.3	 (69.1,	83.5)	and	75.8	 (68.4,	83.2)	 in	Arms	A,	B	and	C,	respec‐
tively.	Baseline	mean	(95%	CI)	EQ‐5D‐5L	IUS	scores	were	0.72	(0.63,	
0.81),	 0.67	 (0.52,	 0.82)	 and	 0.74	 (0.67,	 0.81)	 in	 Arms	 A,	 B	 and	 C,	
respectively.	 For	 some	 dimensions	 of	 the	 EQ‐5D‐5L	 (eg,	 anxiety),	
a	 considerable	 number	 of	 participants	 reported	 “never”	 having	 a	
TA B L E  2  Haemophilia‐related	quality	of	life	in	adults.	Mean	Haem‐A‐QoL	domain	and	total	scores	at	baseline
Haem‐A‐QoL 
domain
Previously on episodic BPAs Previously on prophylactic BPAs
Arm A: Emicizumab prophylaxis 
n = 29 
Mean scorea (95% CI)
Arm B: No prophylaxis 
n = 16 
Mean scorea (95% CI)
Arm C: Emicizumab prophylaxis 
n = 21 
Mean scorea (95% CI)
Physical	Health 52.4	(44.4,	60.4) 57.2	(46.1,	68.3) 59.5	(48.0,	71.1)
Feelings 36.9	(27.2,	46.5) 32.4	(18.0,	46.8) 47.9	(32.6,	63.2)
View	of	Yourself 45.3	(37.6,	53.1) 48.8	(38.7,	58.8) 52.1	(40.9,	63.4)
Sports	&	Leisureb 58.0	(45.4,	70.6) 66.9	(55.4,	78.4) 67.3	(47.8,	86.8)




Treatment 36.3	(26.6,	46.0) 45.7	(34.0,	57.4) 48.5	(37.5,	59.5)
Future 48.4	(38.7,	58.1) 55.3	(41.6,	69.0) 54.5	(44.0,	65.0)
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problem	at	baseline,	and	this	may	have	limited	the	ability	to	detect	
an	improvement	in	some	items.










95%	CI:	−0.25,	−0.07;	P	=	0.0014).	Throughout	 the	 study,	 a	greater	
proportion	 of	 participants	 in	 the	 emicizumab	 prophylaxis	 groups	
F I G U R E  2  Haem‐A‐QoL	(adults)	“Total”	score.	Scale	ranges	from	0	(no	impairment)	to	100	(high	impairment).	BPA,	bypassing	agent;	CI,	
confidence	interval;	Haem‐A‐QoL,	Haemophilia	Quality	of	Life	Questionnaire	for	Adults;	QW,	once	a	week.	A.	Mean	score	over	time.	B.	
Cumulative	distribution	plot	of	transformed	“Total”	change	scores	from	baseline	to	week	25
Mean 'Total' score over time (A)
Cumulative distribution plot of transformed ‘Total’ change scores from baseline to week 25(B)
Improvement Deterioration
Change from baseline













































Arm A: Emicizumab prophylaxis (prior episodic BPAs)
Arm B: No prophylaxis
Arm C: Emicizumab prophylaxis (prior prophylactic BPAs)
Arm A, n: 29 27 27 28 28 28 26
Arm B, n: 16 16 14 15 15 14 14
Arm C, n: 21 19 15 12 10 9 8
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(Arms	A	and	C)	 than	 in	 the	no	prophylaxis	group	 (Arm	B)	 achieved	
an	improvement	exceeding	responder	thresholds	(Figure	S1C,D).39,40
Mean	EQ‐VAS	and	EQ‐5D‐5L	 IUS	 scores	were	generally	 lower	
(worse)	on	days	when	bleeding	occurred	than	on	regularly	scheduled	
reporting	days	(Figure	S2).
3.1.5 | Work/school absences and hospitalizations
The	 number	 of	 participants	 working	 before	 and	 during	 the	 study	
was	11	in	the	emicizumab	prophylaxis	group	(Arm	A)	and	7	in	the	no	
prophylaxis	group	 (Arm	B).	 In	 the	4	weeks	before	study	entry,	 the	
F I G U R E  3  Haem‐A‐QoL	(adults)	Physical	Health	Domain	score.	Scale	ranges	from	0	(no	impairment)	to	100	(high	impairment).	BPA,	
bypassing	agent;	CI,	confidence	interval;	Haem‐A‐QoL,	Haemophilia	Quality	of	Life	Questionnaire	for	Adults;	QW,	once	a	week.	A,	Mean	
score	over	time.	B,	Cumulative	distribution	plot	of	transformed	“Physical	Health”	domain	change	scores	from	baseline	to	week	25
Mean 'Physical Health' score over time 





















Arm A: Emicizumab prophylaxis (prior episodic BPAs)
Arm B: No prophylaxis




29 27 27 28 28 28 26
16 16 14 15 15 14 14
21 19 15 12 10 9 8
1 5 9 13 17 21 25
   
   


























Responder threshold: –10 points
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mean	proportion	of	missed	work	days	 (95%	CI)	was	5%	 (0%,	12%)	
in	Arm	A	 and	 13%	 (2%,	 25%)	 in	Arm	B.	 This	 remained	 essentially	
unchanged	 in	both	groups	 (7%	 [0%,	15%]	 and	14%	 [8%,	19%],	 re‐
spectively)	during	the	study.	For	participants	previously	treated	with	














The	 results	 of	 this	 analysis	 demonstrate	 that	 participants	 receiv‐
ing	once	weekly	emicizumab	prophylaxis	 in	HAVEN	1	experienced	
statistically	 significant	 and	 clinically	 meaningful	 improvements	 in	
haemophilia‐specific	 QoL	 and	 overall	 health	 status.	 On	 all	 meas‐
ures,	 improvements	were	 seen	as	 early	 as	week	5	 and	maintained	






TA B L E  3  Effect	of	emicizumab	prophylaxis	on	haemophilia‐related	quality	of	life	in	adults.	Mean	change	from	baseline	to	week	25	in	
Haem‐A‐QoL	domain	and	total	scoresa
Domain
Previously on episodic BPAs Previously on prophylactic BPAs
Arm A: Emicizumab prophylaxis n = 25b 
Mean Δ (95% CI)
Arm B: No prophylaxis n = 14b 
Mean Δ (95% CI)
Arm C: Emicizumab prophylaxis n = 8b 
Mean Δ (95% CI)
Physical	Healthc −19.8	(−28.8,	−10.8) 0.4	(−9.2,	9.9) −15.0	(−36.2,	6.2)
Feelings −14.8	(−25.9,	−3.6) 6.7	(−1.2,	14.6) −14.1	(−35.1,	7.0)
View	of	Yourself −12.2	(−19.9,	−4.6) 2.5	(−6.0,	11.0) −6.3	(−21.0,	−8.5)
Sports	&	leisurec,d −9.8	(−21.6,	2.0) 2.1	(−5.7,	9.8) −40.8	(−115.6,	33.9)
Work	&	Schoold −13.1	(−20.8,	−5.3) 8.3	(−9.8,	26.5) −21.9	(−46.3,	2.6)
Dealing	with	Haemophilia −4.0	(−11.7,	3.7) 8.3	(−2.0,	18.7) −20.8	(−35.7,	−5.9)
Treatment −9.3	(−16.5,	−2.0) 2.2	(−4.6,	9.1) −24.6	(−50.1,	0.9)
Future −13.8	(−23.6,	−4.0) −2.5	(−15.3,	10.3) −17.5	(−36.1,	1.1)
Family	Planningd 10.9	(−4.6,	26.3) −3.1	(−16.5,	10.3) −43.8	(NE)e
Partnerships	&	Sexuality −2.3	(−12.6,	8.0) 3.6	(−5.4,	12.6) −6.3	(−17.3,	4.8)














Arm C: Emicizumab 
prophylaxis 
n = 13b 





















of	 the	 scale	 regardless	 of	 previous	 treatment	 regimen,	 suggesting	















resulted	 in	 statistically	 significant	 improvements	 in	 overall	 health	
status	as	measured	by	the	EQ‐VAS	and	EQ‐5D‐5L	IUS.	As	has	been	
seen	 in	 other	 studies,24,42	 EQ‐5D‐5L	 IUS	 scores	 were	 generally	












Mean EQ-5D-5L IUS over time (B)





















Arm A: Emicizumab prophylaxis (prior episodic BPAs)
Arm B: No prophylaxis
Arm C: Emicizumab prophylaxis (prior prophylactic BPAs)
Arm A, n: 33 31 32 32 32 32 30
Arm B, n: 18 17 16 17 17 17 16



















Arm A: Emicizumab prophylaxis (prior episodic BPAs)
Arm B: No prophylaxis
Arm C: Emicizumab prophylaxis (prior prophylactic BPAs)
1 5 9 13 17 21 25
Time (wk)
Arm A, n: 33 31 32 32 32 32 30
Arm B, n: 18 17 16 17 17 17 16
Arm C, n: 48 40 38 33 27 25 21
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not	 disease‐specific	 provides	 a	 valuable	 complement	 to	 the	 dis‐









This	 analysis	 of	 HAVEN	 1	 demonstrates	 that	 the	 substantial	 re‐
ductions	 in	 bleeding	 seen	 with	 emicizumab	 prophylaxis29 were 
accompanied	by	substantial	 and	meaningful	 improvements	 in	 the	
daily	lives	of	PwHA	with	inhibitors.	Improvements	in	haemophilia‐
specific	QoL	 and	 overall	 health	 status	were	 apparent	 as	 early	 as	
the	 first	 assessment	 after	 the	 start	 of	 treatment	 and	maintained	
throughout	 the	 study.	 Importantly,	 improvements	 among	 par‐
ticipants	 previously	 treated	with	 prophylactic	BPAs	mirrored	 the	
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